BridgeBio Shares Hit 52-Week High as AstraZeneca Trial Failure Boosts Rival Drug's Prospects

Shares of BridgeBio Pharma (BBIO) surged to a 52-week intraday high of $93.42 earlier in the month before closing the session 15% higher, adding roughly $2.3 billion in market value, after AstraZeneca (AZN) disclosed a late-stage clinical failure that investors believe strengthens BridgeBio's position in the market for a rare heart condition.

The rally was triggered by AstraZeneca's announcement that its phase III CARDIO-TTRansform study evaluating Wainua in patients with transthyretin amyloid cardiomyopathy, or ATTR-CM, failed to meet its primary endpoint. The result was widely interpreted as a competitive boon for Attruby, BridgeBio's FDA-approved treatment for the same condition and currently its only commercialized product.

Attruby received FDA approval in November 2024 for adults with ATTR-CM. Its commercial launch has been strong: BridgeBio recorded $362.4 million in US Attruby sales in 2025, its first full year on the market, and nearly $181 million in the first quarter of 2026 alone, suggesting an annualized run rate well in excess of its debut-year performance.

With AstraZeneca's Wainua now facing questions over its clinical viability in ATTR-CM, Attruby's position in the space could prove more durable than previously anticipated — a prospect that appears to have driven the sharp re-rating of BridgeBio's shares.